Cargando…
Expression of MDR1, HIF-1α and MRP1 in sacral chordoma and chordoma cell line CM-319
BACKGROUND: Chordoma was a typically slow-growing tumor. The therapeutic approach to chordoma had traditionally relied mainly on surgical therapy. And the main reason for therapeutic failure was resistance to chemotherapy and radiotherapy. However the refractory mechanism was not clear. The aim of t...
Autores principales: | Ji, Zhengang, Long, Hua, Hu, Yunsheng, Qiu, Xiuchun, Chen, Xiang, Li, Zhao, Fan, Degang, Ma, Baoan, Fan, Qingyu |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3017037/ https://www.ncbi.nlm.nih.gov/pubmed/21143841 http://dx.doi.org/10.1186/1756-9966-29-158 |
Ejemplares similares
-
Sacral Chordoma: Challenging for Resection Margin
por: Lee, Seung-Hyun, et al.
Publicado: (2014) -
Solamargine inhibits proliferation and promotes apoptosis of CM-319 human chordoma cells through suppression of notch pathway
por: Liu, Junqi, et al.
Publicado: (2019) -
Computer Navigation-aided Resection of Sacral Chordomas
por: Yang, Yong-Kun, et al.
Publicado: (2016) -
Combined Therapy for Distant Metastasis of Sacral Chordoma
por: Özkal, Birol, et al.
Publicado: (2015) -
Surgical Treatment of Sacral Chordoma: The Role of Laparoscopy
por: Efetov, Sergey K., et al.
Publicado: (2020)